Table 5 Sexually-related outcomes
Author Year Country | Study design | Number of patients | Withdrawals—dropouts | Intervention Breast reduction Mean (SD) | Control No surgery Mean (SD) P values of intergroup difference if not state otherwise | Comments | Directness* | Study limitations* | Precision* |
|---|---|---|---|---|---|---|---|---|---|
Beraldo 2016 Brazil [41] | RCT | I: 30 C: 30 | I: 1 C: 3 | Sexual function Baseline: 24.7 (8.8) 6 months: 27.5 (6.9) | Sexual function Baseline: 23.9 (9.6) p = 0.96 6 months: 22.5 (9.3) p < 0.001 MD 5.0 | Female Sexual Function Index (FSFI). The questionnaire includes 19 questions on sexual activity during the last 4 weeks. It has 6 domains: desire, arousal, lubrication, orgasm, satisfaction, and discomfort/pain. A higher score means a better function. A total score of 26.55 or less indicates sexual dysfunction A MID of 4.2 has been suggested for FSFI [65] | ? | ? | ? |
Andrade 2018 Brazil [42] | Non-randomized controlled study | I: 50 C: 50 | NR | Sexual well-being 6 months-1 year: 88 (21–100) median (range) | Sexual well-being 29 (0–78) median (range) p = 0.001 MD 66 | Sexual well-being domain of BREAST-Q (reduction/ mastopexy module) Score 0–100, a higher score means better outcome Baseline values are not given |  +  | - | ?/ +  |
Janik 2019 Poland [62] | Non-randomized controlled study | I: 75 C: 27 | NR | Sexual quality of life 12–36 months: 76.7 (11.6) (mean follow-up 23.6 months) | Sexual quality of life 64.4 (13.7) p < 0.01 MD 12 | Sexual Quality of Life-Female (SQoL-F): 18 items, each scored from 1–6, total score 18–108 Higher score better |  +  | - | - |
|  |  |  |  | Sexual function 12–36 months: 27.4 (9.1) | Sexual function Pre-operative: 21 (11.4) p = 0.03 | Female Sexual Function Index (FSFI). Higher score better |  |  |  |
|  |  |  |  | Sexual well-being 12–36 months: 72 (14) | Sexual well-being Pre-operative: 39.3 (14.5) p < 0.01 | Sexual well-being domain of BREAST-Q (reduction/ mastopexy module). Baseline values not reported |  |  |  |